SIGA - Sector: Healthcare---Industry: Biotechnology & Drugs

[stocks2watch2]

Had a big run yesterday on the news, then pulled back. Now the gap is filled. Bought 15000 this am.

NEW YORK, Sep 27, 2005 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA, Trade) announced today that it has entered into a $3.2 million, one year contract with the United States Army Medical Research and Material Command (USAMRMC). The agreement, for the rapid identification and treatment of anti-viral diseases, is funded through the United States Air Force (USAF). SIGA's efforts will aid the USAF Special Operations Command in its use of computational biology to design and develop specific countermeasures against the biological threat agents Smallpox and Adenovirus. Smallpox is a Center for Disease Control and Prevention (CDC) Category A biothreat agent, and Adenovirus is a cause of significant respiratory infectious disease, both of which may impair the combat readiness of USAF Personnel.

SIGA's computational approach to the development of countermeasures is designed to interface with USAF programs for the identification of potential agents of bioterrorism, and will provide a key building block in the foundation of a rapid response capability to biological threat agents. War-fighters and special operations forces, in particular, may be called upon to operate in environments containing known or unknown pathogens. Until these pathogens can be accurately identified and neutralized, our war fighters, Special Operations Forces and our nation remain vulnerable to the release of both natural and engineered viral pathogens.

"I am very excited about our relations with the USAF and SIGA's ability to participate in an effort which, I believe, is of crucial importance to our nation," said SIGA's CEO, Dr. Bernard L. Kasten. "I see a clear opportunity to continue working with the USAF in the future and to further advance SIGA's antiviral counter measure programs."

"We welcome the opportunity to work with our USAF colleagues to develop this important biological defense capability", said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA


Edit of the Thread Name, "SIGA,buying on the pullback"
These types of messages with the Ticker Symbol become out of date as time goes passes.
Thank You ,
setravis

[stocks2watch2]

SIGA,Gets an extension to 3-21-06. Keep an eye on it. It may have another big run. Lots of recent good news.

On September 1, 2005, SIGA responded to the notice and indicated that as of August 31, 2005, SIGA believed it had regained compliance with the Stockholders' equity requirement and that its stockholders' equity on August 31, 2005 was in excess of $2,500,000. SIGA noted that its stockholders' equity deficiency resulted from SIGA's decision to accelerate the development and related costs of its lead Smallpox anti-viral drug, SIGA-246. The development work is currently being funded through a two years grant from the National Institutes of Health ("NIH"). Approximately $1,000,000 of the $1,700,000 in development work incurred in the first half of 2005 was to be funded during the second year of the grant which began on August 1, 2005. The second year funding was approved by the NIH and SIGA was able to recognize the related revenues subsequent to the filing of the Form 10-Q for the period ended June 30, 2005.

On September 22, 2005, SIGA received an additional notice from NASDAQ, indicating that the Nasdaq Staff believes that SIGA provided a definitive plan evidencing its ability to achieve and sustain compliance with the Rule, and as such, has determined to grant SIGA an extension of time to evidence compliance upon the filing of its periodic report for the quarter ended September 30, 2005. The Nasdaq Staff will continue to monitor SIGA's ongoing compliance with the stockholders' equity requirement and, if at the time of SIGA's next periodic report SIGA does not evidence compliance; it may be subject to delisting.

[stocks2watch2]

October 06, 2005 08:00:03 (ET)


NEW YORK, Oct 06, 2005 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA, Trade) today announced that the company's lead smallpox compound, SIGA-246, completely protected golden ground squirrels from lethal doses of monkeypox virus. Monkeypox virus is closely related to human smallpox virus, and causes a similar disease in both monkeys and humans. SIGA-246, administered orally, demonstrated significant antiviral activity against the golden ground squirrel model of monkeypox disease. The study was conducted in the BSL-3 facility at the University of Texas Medical Branch (UTMB). SIGA had announced in October 2004 that it had established the efficacy of SIGA-246 in several mouse models.

"The successful outcome of this study is important," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "It is the first demonstration of SIGA-246 efficacy against monkeypox in a lethal challenge model using a genetically diverse population of wild rodents."

Smallpox virus is considered one of the most significant threats for use as a biowarfare agent due to the fact that since 1972 people in the United States have not been vaccinated against it. Smallpox is very easily transmitted from person to person, and has high mortality rates (30-60%) with 90% morbidity. Weaponized smallpox virus may have an incubation period as short as 3-7 days. It is classified as a Category A agent by the Center for Disease Control (CDC). Mass immunizations of the general population using the current live vaccines are not recommended. Available vaccines are known to cause complications in certain individuals, including encephalitis, myocarditis, disseminated vaccinia virus infection, and death. At present there is no treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions.

SIGA's CEO Dr. Bernard L. Kasten stated, "The results of this study demonstrate that SIGA-246 is an orally active compound that can prevent the systemic spread of monkeypox virus. The drug performance continues to be very promising as we expedite its development."

[Gu$tavo]

I'm in since 28-sep @ 1.0097 on your call, at that time there was really low risk on downside, then that was the reason I liked.... so, (so far) good "pick" and good "Timing" of you ... and thanks.
But,,, now with this last news what dou you think this really mean for SIGA...

[stocks2watch2]

 I really like SIGA they have a lot in the works.and the goverment is giving them millions. Theres a fear of bio terrorism. I bought 15000 more yesterday. Once they get notice from the nasdaq that they won't be delisted I think we'll see new highs.

NEW YORK (MarketWatch) -- Siga Technologies shares gained 18.5% to $1.16 on Thursday after the company said SIGA-246, its lead smallpox compound, "completely protected" golden ground squirrels from lethal doses of monkeypox virus in a recent study. The company said the study was conducted in the BSL-3 facility at the University of Texas.


SIGA scientists have developed methods that allow essentially any gene sequence to be expressed in GRAS gram-positive bacteria, with the foreign protein being displayed on the surface of the live recombinant organisms.  Since these organisms are inexpensive to grow and are very stable, this technology affords the possibility of rapidly producing live recombinant vaccines against any unwanted biological agent that might be encountered such as Bacillus anthracis (anthrax) or Smallpox.  Our Chief Scientific Officer, Dennis Hruby, has over 20 years experience working on smallpox-related research and has been leading a SIGA/Oregon State University consortium working on and antiviral drug development project for the past two years.

The market potential for our biological warfare defense products has not yet been quantified beyond the potential to obtain a share of the approximately $9 billion the federal government is committing to support research in the coming year.  The government’s purchase of approximately $800 million worth of the existing smallpox vaccine to have an inventory on hand if needed is evidence of market’s potential.

Anti-Smallpox Drugs: While deliberate introduction of any pathogenic agent would be devastating, the one that holds the greatest potential for harming the general U.S. population is smallpox.  At present there is no effective approved drug with which to treat or prevent smallpox infection.  To address this serious risk, SIGA scientists have identified two key smallpox proteinases and are using their expertise in the design of proteinase inhibitors to develop an effective antiviral drug that can be used to ensure our future safety.

[Gu$tavo]

 
top    SIGA Stats    Symbol Search
 
 
Time B/S Shares  Price     
 
15:34:17.073 B 200  1.2600 
 
15:34:17.073 B 1,000  1.2600 
 
15:33:11.620 B 500  1.2500 
 
15:33:08.517 B 300  1.2500 
 
15:33:03.669 B 180  1.2500 
 
15:33:03.669 B 1,020  1.2500 
 
15:32:57.826 B 1,880  1.2500 
 
15:32:57.826 B 100  1.2400 
 
15:28:24.337 B 1,000  1.2400 
 
15:17:50.660 B 2,243  1.2300 
 
15:17:50.660 B 200  1.2300 
 
14:54:20.401 B 300  1.2300 
 
14:53:04.402 B 100  1.2300 
 
14:53:04.402 B 600  1.2300 
 
14:43:24.905 S 500  1.2200 
 
14:43:24.905 S 500  1.2200 
 
14:21:52.876 S 100  1.2200 
 
14:21:52.876 S 500  1.2200 
 
14:03:40.335 B 1,800  1.2000 
 
14:03:40.335 B 1,700  1.2000 
 

[stocks2watch2]

Strong close on good volume,look for more upside next week.

[stocks2watch2]

SIGA, Having another good day. I believe there is still some upside here, but I will have to take a little profit here, up 35%.

 
 

[stocks2watch2]

SIGA, Making another run today. There should be no problem with delisting now. I am selling all but 5000 into todays rally.

[Gu$tavo]

I won't sell  ... I'm waiting for price above 1.40 ...  1.75 is resistance for me.. the trend is clearly up for 20 sesions now (the general market can't say the same  )....
good luck ..

[stocks2watch2]

Bought back in @ .95.

1-05-06  SIGA Reports on Correspondence With Nasdaq


NEW YORK, Jan 05, 2006 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA). As previously disclosed, SIGA entered into a Securities Purchase Agreement, dated November 2, 2005, with four investors for the issuance and sale of 2,000,000 shares of SIGA's common stock at $1.00 per share for aggregate consideration of $2,000,000 and certain warrants. The investors were also entitled to purchase additional shares of SIGA's common stock for a gross amount of up to $2,000,000 at an initial price of $1.10 per share for a period of 90 trading days following the effectiveness of a registration statement.

On December 9, 2005, SIGA was verbally notified by The Nasdaq Stock Market that it was in violation of the shareholder approval rules set forth Marketplace Rule 4350(i)(1)(D)(ii) because the share issuance cap found in the Warrant and Additional Investment Right agreements was not in compliance with IM-4350-2, which requires a share issuance cap to apply for the life of the transaction unless shareholder approval is obtained.

Subsequently, on December 13, 2005, SIGA provided The Nasdaq Stock Market with copies of signed amended and restated Warrant and Additional Investment Right agreements, which evidence a share issuance cap which complied with IM-4350-2.

As a result, on December 30, 2005, SIGA received a letter from The Nasdaq Stock Market informing it that The Nasdaq Stock Market had determined, based on the above described actions that SIGA had regained compliance with the Rule and that the matter was now closed.

[stocks2watch2]

SIGA, Up 16%. Can't find any news on it. Sold 1/2 @ 1.15.

[wrangler]

SIGA : has been trading up for the last three day's and is now testing 1.60 resistance

[REALDEALS21]

Breakout today ??

[stocks2watch2]

SIGA Technologies: PharmAthene awarded $213 mln Department of Defense contract for advanced development of Protexia
Briefing.com - September 25, 2006 4:02 PM ET
   
 
Related Quotes
Symbol   Last Chg
SIGA Trade 1.0599 0.00
Real time quote.
 
 PharmAthene announced today that it has been awarded a multi-year contract valued at up to $213 mln from the Department of Defense U.S. Army Space and Missile Command, for advanced development of the co's broad spectrum chemical nerve agent prophylaxis, Protexia. Under the contract, PharmAthene will be responsible for the conduct and oversight of all product development activities. The initial stage of development, for which $34.7 mln has been allocated, includes manufacturing process development, preclinical safety and toxicity testing, submission of an Investigational New Drug Application with the FDA, and initiation of a Phase I clinical trial. This communication is being made in respect of the proposed merger transaction involving SIGA and PharmAthene. In addition, SIGA has filed a preliminary proxy statement with the SEC in connection with the transaction and will mail the definitive proxy statement to SIGA shareholders of record at the record date for the special meeting of the shareholders to be held to provide approvals relating to the proposed transaction.